Evolving Evidence in the Management of Patients with Non-Small Cell Lung Cancer:
Clinical Pearls for the Community Practitioner
Pre-test

Questions marked with a * are required
100%
Contact Information
Which statement regarding the findings of the phase 3 clinical trial, EMPOWER-Lung 1, investigating the role
of cemiplimab vs chemotherapy in patients with stage IV NSCLC without actionable driver mutations and PD-
L1 expression ≥50%, is true regarding patients who received cemiplimab?
Alfred is a 67-year-old man who has been diagnosed with advanced NSCLC with no actionable mutations and
a PD-L1 TPS score of 90%. You determine that he is a good candidate for immune checkpoint inhibitor
therapy. Based on current practice guidelines, which of the following regimens would be most appropriate in
the first-line setting for this patient?
Joyce is a 72-year-old woman who has been diagnosed with advanced NSCLC with no actionable mutations
and a PD-L1 TPS score of 80%. You determine that she may be a good candidate for single-agent PD-1/PD-L1
inhibitor therapy, using either atezolizumab, cemiplimab or pembrolizumab. She mentions her friend with
NSCLC who was prescribed dual PD-1/PD-L1 inhibitor therapy and would prefer this more aggressive regimen
to “nip this problem in the bud.” How would you counsel this patient?
Tony is a 66-year-old man who has been diagnosed with advanced NSCLC and a PD-L1 TPS score of 40%. You
recommend combination therapy comprised of platinum doublet chemotherapy and immunotherapy. Tony
responds, saying “Do I have to take chemotherapy? It terrifies me.” Which of the following would be the best
response to Tony’s concerns?
Powered by QuestionPro